In terms output per dollar spent, drug development has never been as slow as it is now. As we have so many more scientific techniques than in previous decades so this slowing should be very surprising. Ben and Saloni talk to Ruxandra Teslo about what can be done about this. Should we have more vouchers so special conditions can bypass some of the FDA's bureaucracy? Why are so many biotech companies moving to Australia? How can we reform ethics boards? Which regulations make clinical trials more reliable? Why is there so much more money being spent on curing osteoporosis?
You can also listen to the episode on Apple podcasts, Spotify, and YouTube.
